Belantamab Mafodotin (Blenrep), Bortezomib, Dexamethasone

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Belantamab mafodotin (Blenrep) in combination with bortezomib and dexamethasone, 70 mg and 100 mg per single-use vials. Indication: Belantamab mafodotin in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy.